Photodynamic therapy relieves colitis and prevents colitis-associated carcinogenesis in mice.
Fiche publication
Date publication
mai 2015
Journal
Inflammatory bowel diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEZDETNAYA-BOLOTINE Lina, Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Reinhard A, Bressenot A, Dassonneville R, Loywick A, Hot D, Audebert C, Marchal S, Guillemin F, Chamaillard M, Peyrin-Biroulet L, Bezdetnaya L
Lien Pubmed
Résumé
Inflammatory bowel diseases are incurable illnesses of the gastrointestinal tract, which substantially enhance the risk of developing colorectal carcinogenesis. Conventional photodynamic therapy is a clinically approved therapeutic modality used in the treatment of neoplastic diseases. Recent preclinical and clinical studies have shown that photodynamic therapy with low doses of photosensitizer and/or light improves inflammatory conditions, including colitis. This study aims therefore at investigating the therapeutic potential of low-dose photodynamic therapy (LDPDT) with a liposomal formulation of meta-tetra(hydroxyphenyl)chlorin (namely Foslip) in the prevention of colitis-associated cancer in mice.
Mots clés
Animals, Colitis, chemically induced, Colonic Neoplasms, etiology, Colonoscopy, Cytokines, metabolism, Enzyme-Linked Immunosorbent Assay, Female, Gene Expression Profiling, Humans, Immunoenzyme Techniques, Lymphoma, Large B-Cell, Diffuse, drug therapy, Mesoporphyrins, therapeutic use, Mice, Mice, Inbred C57BL, Photochemotherapy, Photosensitizing Agents, therapeutic use
Référence
Inflamm. Bowel Dis.. 2015 May;21(5):985-95